What is microcurrent therapy and how is it different from TENS or EMS?
The basics of the method are briefly presented on the microcurrent therapy category page and in the electrotherapy methods articles. I discuss the three methods together — TENS, EMS, and MENS — in my comparative article TENS, EMS and MENS comparison. This article is the standalone main piece on microcurrent: it includes joint applications (microcurrent and joint inflammation), practical application (microcurrent treatment in practice), and cosmetic use (G-Pulse face treatments).
Key point
Microcurrent does not replace active TENS pain relief or EMS muscle strengthening — it is another modality that works on a complementary principle. Recent clinical evidence shows contribution to standard care in acute knee pain (Lawson 2021, PMID 33095658), chronic wound healing (Avendaño-Coy 2022 meta-analysis, PMID 34903470) and pressure ulcer healing in older adults (Avendaño-Coy 2022, PMID 36011679). In sports recovery, Naclerio 2021 (PMID 33295832) observed a reduction in delayed onset muscle soreness (DOMS). For home use, the Premium 400, Genesy 300 Pro, the Genesy 600 / 1500 / 3000 multifunction family and TensCare UniPro microcurrent programs are the most commonly chosen devices.
How does microcurrent affect the body?
The effect of microcurrent is fundamentally based on electrical processes at the cellular level. According to the 2025 review by Jonik (PMID 40821620) the main proposed mechanisms of action are below. It is important to emphasize: clinical results are encouraging, but the detailed molecular background requires further research.
A measurable natural (endogenous) electric potential difference exists between the skin and underlying tissues — typically a resting membrane potential between −50 and −90 mV across cell membranes. When an injury or wound occurs, this potential gradient changes and a flow that promotes cell migration and wound-edge regeneration (the so-called "current of injury") is generated. From an engineering perspective, microcurrent therapy mimics these endogenous electrical phenomena, thereby supporting natural regenerative processes. The Avendaño-Coy 2022 meta-analysis (PMID 34903470, 8 RCTs, n=337) found that microcurrent combined with standard wound care reduced wound area by an average of 8.3 cm² more and shortened healing time by 7 days compared with standard care alone.
The 2025 Jonik review (PMID 40821620) reports that microcurrent therapy in in vitro models promotes cell membrane stabilization, fine-tuning of calcium ion utilization, and regenerative activity of connective tissue (fibroblasts, collagen). These observations may explain why clinical acceleration of wound healing (Avendaño-Coy 2022; meta-analysis and pressure ulcer RCT), scar tissue rehabilitation (Gregory 2025, PMID 40465410) and certain chronic joint complaints (Iijima 2021, PMID 34589695) are seen.
Recent reviews (Jonik 2025; Iijima 2021) consistently mention the potential for inflammation modulation. This could explain observed pain reductions in acute knee pain (Lawson 2021, PMID 33095658) and some hard-to-heal wounds (Ofstead 2020, PMID 32654615). Important: detailed molecular pathways (e.g., net changes in ATP synthesis) require further confirmation in human in vivo studies — therefore precise percentage claims about ATP increases often repeated in marketing should be avoided. Inflammation reduction is not immediate, not guaranteed, and does not replace pharmacologic therapy: acute inflammatory processes (feverish or infectious) require medical evaluation.
Despite its low intensity, microcurrent can produce analgesic effects: the 2025 randomized, double-blind, sham-controlled crossover trial by Martuliak (PMID 40900299, n=71 musculoskeletal pain patients, mostly with back pain) reported that Rebox microcurrent treatment reduced average pain by 2.2 points on the NRS compared with placebo (Cohen's d = 0.75, p = 0.002), with a noticeable placebo response in the sham-first arm.
The mechanism is still under investigation but may include modulation of peripheral nerve fiber excitability and effects at the level of the gate control theory. Clinical trials typically observed effects with daily 3-hour sessions (Lawson 2021) or 4–5 sessions per week (Martuliak 2025). The method is primarily recommended as an adjunct — it does not replace medical diagnosis or necessary pharmacologic treatment.
What clinical indications can microcurrent be used for?
The 2025 narrative review by Jonik (PMID 40821620) and the 2021 systematic review by Iijima (PMID 34589695) convey a consistent message: microcurrent therapy is a supportive modality — not a standalone cure. The following indications currently have the strongest evidence for a supportive role:
The 2021 double-blind RCT by Lawson (PMID 33095658) in 52 participants (26 microcurrent + 26 placebo, daily 3 hours, 4 weeks) showed a statistically significant pain reduction at week 3 on the Numeric Pain Rating Scale (p < 0.01). The 2021 Iijima systematic review (PMID 34589695) rated the evidence for knee pain as high by GRADE. Important: the placebo response was also significant — microcurrent is an adjunct to physiotherapy and lifestyle interventions, not a replacement.
The 2022 Avendaño-Coy meta-analysis (PMID 34903470, 8 RCTs, n=337) found that microcurrent plus standard wound care produced 8.3 cm² smaller wound area and 7 days shorter healing time than standard care alone. The 2022 Avendaño-Coy RCT focusing on pressure ulcers (PMID 36011679, n=30) showed a 25% better improvement in PUSH score. Important: wound management is a specialist task; microcurrent is an adjunct here. See: Leg ulcer with muscle stimulation to aid healing.
The 2021 trial by Naclerio (PMID 33295832, n=18 male cross-country runners, 8 weeks, daily 3 hours microcurrent after training) significantly reduced DOMS sensation at 24 and 48 hours and produced more favorable body composition changes (reduced lower-body fat). Aerobic performance (maximal aerobic speed) increased similarly in both groups — microcurrent did not add training effectiveness. See related: muscle stimulation for athletes.
The 2025 Martuliak Rebox study (PMID 40900299) investigated kHz-range microcurrent-like treatment primarily in patients (n=60) presenting with back muscle pain. It found an average pain reduction of 2.2 NRS points over sham. Detailed joint application is discussed in the microcurrent therapy for joint inflammations spoke article. Important: every joint complaint requires medical diagnosis to clarify the underlying disease (osteoarthritis, RA, etc.).
The 2025 Gregory pilot studies (PMID 40465410, n=17 systemic sclerosis patients, 1–2 days, frequency-specific microcurrent) showed an average 40% improvement in hand function (Cochin score, p < 0.001). Cosmetic uses — facial muscle stimulation, tone of fine mimic muscles — are detailed in the G-Pulse face treatments cluster article. Important: these effects are modest and should be positioned as complementary, not as standalone aesthetic procedures.
What does microcurrent feel like, and how does it differ from TENS?
Classic TENS and EMS treatment is perceptible: tingling under the skin and muscle contractions occur. Due to its low intensity, microcurrent is typically subsensory, meaning the user does not feel a direct electrical sensation. Some devices may produce a light tingling at the edges of the treatment area, but the classic "muscle twitch" of EMS is absent. This characteristic makes the method particularly suitable for sensitive or painful areas (recently healed skin, inflamed joints, edges of acute wounds) where TENS would be too intense.
| Characteristic | TENS | EMS | MENS (microcurrent) |
|---|---|---|---|
| Current intensity | 0–50 mA | 0–80 mA | 10–600 µA |
| Sensation | perceptible tingling | muscle twitch | typically not perceptible |
| Goal | pain relief | muscle strengthening, regeneration | supporting cellular regeneration |
| Frequency | 2–150 Hz | 5–120 Hz | 0.3–500 Hz |
| Typical session | 20–30 minutes | 20–30 minutes | 20–60 minutes, often several hours per day |
| Onset of effect | during / immediately after treatment | after 4–6 weeks | after 2–4 weeks |
| Home device | TensCare UniPro, Tens Eco 2 | Globus Genesy, Lito series | Genesy 1500/3000, TensCare UniPro |
The detailed methodological comparison can be read in the TENS, EMS and MENS cluster article.
Home microcurrent devices and practical application
Several device families on the market offer microcurrent programs. In MediMarket's portfolio the following multifunction devices include factory microcurrent protocols:
- Premium 400 – 4 channels, factory MENS programs for joint and wound-healing support.
- Globus Genesy 1500 – 2 channels, basic microcurrent, TENS and EMS package for multifunctional home use.
- TensCare UniPro – compact 2-channel device with simplified TENS, EMS and MENS programs.
Details of practical application — electrode placement, session length, frequency, programs — are available in the spoke article microcurrent treatment in practice.
Key point
Typical protocol parameters for home microcurrent treatment: 20–60 minute sessions, 1–3 times daily, for 2–8 weeks. In many clinical trials (Lawson 2021, Avendaño-Coy 2022) treatments were applied for 3–10 hours daily — therefore microcurrent devices are specifically designed for long usage (low power consumption, gentle electrodes). Effects usually become noticeable after 2–4 weeks, and current evidence positions microcurrent as a supportive modality — it does not replace primary care.
When NOT to use microcurrent treatment?
Although microcurrent has a favorable safety profile due to its low intensity, it is not free of adverse effects. General electrotherapy contraindications also apply here; details are discussed in the electrical treatment contraindications and electrical treatment and implants articles.
- Pacemaker, ICD, implanted neurostimulator – contraindicated near any electronic implant unless explicitly cleared by a cardiologist/arrhythmologist.
- Active malignant tumor in the treatment area – regenerative effects could pose a risk.
- Pregnancy – avoided for general maternal and fetal safety reasons.
- Active deep vein thrombosis (DVT) in the treatment area – risk of embolization.
- Active skin infection, fresh skin wound (other than the indicated lesion), extensive eczema under the treatment area.
- Carotid sinus / anterior neck region – do not place electrodes near major neck arteries.
- Fever or acute inflammatory processes of unclear origin – medical evaluation first.
- Epilepsy with poorly controlled medication – individualized assessment needed.
- Severe sensory loss in the treatment area – reduces treatment safety.
The advantage of microcurrent is a favorable safety profile, but unsupervised self-treatment in the presence of unclear symptoms can delay diagnosis and appropriate therapy. For new, suspicious, or worsening pain always seek medical consultation.
The place of microcurrent in the electrotherapy system
Microcurrent therapy is one of many modalities — it does not replace other proven methods but complements them. The internal links below help place microcurrent within the broader electrotherapy offering:
- Electrotherapy methods – an overview of the complete methodology.
- TENS, EMS and MENS – what, when, for whom? – comparison of the three core modalities.
- TENS main pillar – pain relief – if the goal is immediate, perceivable pain reduction.
- EMS main pillar – muscle strengthening and regeneration – when muscle mass and strength are the goals.
- Microcurrent and joint inflammation – focus spoke.
- Microcurrent treatment in practice – electrode placement and protocols.
- G-Pulse face treatments in beauty care – cosmetic use.
- Leg ulcer with electrical treatment – wound healing context.
Frequently asked questions about microcurrent therapy
Typically no. The 10–600 µA range falls into the subsensory (below sensory threshold) zone for most users. Some devices may produce a mild tingling at higher intensities (300–600 µA), but the classic TENS tingling or EMS muscle twitch is absent here. This is normal — it does not indicate treatment ineffectiveness.
In clinical trials the effect usually began to appear after 2–4 weeks of regular treatment: Lawson 2021 (PMID 33095658) found a statistically significant improvement in knee pain at week 3; Avendaño-Coy 2022 (PMID 36011679) observed a 16.8% PUSH-score improvement in pressure ulcers after 14 days. In sports recovery (Naclerio 2021, PMID 33295832) DOMS reduction was observed within the first 24–48 hours.
No — it complements, not replaces. Microcurrent therapy is a useful adjunct modality alongside pharmacologic and non-pharmacologic treatments. The 2025 Jonik review (PMID 40821620) and the 2021 Iijima review (PMID 34589695) both clearly position it as complementary. Decisions about stopping or changing medications should always be made by the treating physician.
Protocols used in clinical trials varied: Lawson 2021 used 3 hours daily for 4 weeks, Avendaño-Coy 2022 used 10 hours daily for 25 days, Naclerio 2021 used 3 hours daily for 8 weeks. For home use, factory programs typically recommend 20–60 minute sessions, 1–3 times per day. Exact settings depend on the indication and device type — follow the manufacturer's instructions or consult a physiotherapist.
In the Genesy 1500/3000 family and the TensCare UniPro, TENS, EMS and MENS programs can be used in separate treatment sessions. Simultaneous combination on the same channel is not possible — each modality uses different parameters and aims. You can apply different types of treatment on the same day (e.g., EMS in the morning for training, MENS in the evening for regeneration).
Generally no — only with cardiologist / arrhythmologist approval. Although microcurrent intensity is a fraction of TENS, any electrical treatment near active implants (pacemaker, ICD, neurostimulator) may cause interference. This applies to all electrotherapy modalities — detailed considerations are in the electrical treatment and implants article.
Summary – what microcurrent can and cannot do
The essence of microcurrent (MENS) in brief
- 10–600 µA range, typically subsensory electrical treatment — about 1,000 times lower current than TENS.
- Supported at high GRADE evidence level for acute knee pain (Lawson 2021) and chronic wound healing (Avendaño-Coy 2022, meta-analysis and pressure ulcer RCT) when added to standard care.
- In sports recovery it may reduce DOMS sensation (Naclerio 2021) but does not independently increase training effectiveness.
- Shows clinical contribution in connective tissue regeneration (Gregory 2025) and certain chronic joint complaints (Martuliak 2025).
- Mechanisms include mimicking endogenous electric fields, supporting cellular regeneration, inflammation modulation and pain-signal modulation — detailed molecular pathways need further research.
- The method is a supportive modality — it does not replace primary care, pharmacologic therapy or exercise programs.
- Home devices: Premium 400, Globus Genesy 1500, TensCare UniPro.
- Contraindications (pacemaker, malignancy, pregnancy, DVT, acute infection, etc.) must be strictly observed.
Scientific sources (2020+)
- Iijima H, Takahashi M. Microcurrent Therapy as a Therapeutic Modality for Musculoskeletal Pain: A Systematic Review Accelerating the Translation From Clinical Trials to Patient Care. Archives of Rehabilitation Research and Clinical Translation. 2021;3(3):100145. PMID: 34589695.
- Lawson D, Lee KH, Kang HB, Yang N, Llewellyn T, Takamatsu S. Efficacy of microcurrent therapy for treatment of acute knee pain: A randomized double-blinded controlled clinical trial. Clinical Rehabilitation. 2021;35(3):390-398. PMID: 33095658.
- Avendaño-Coy J, López-Muñoz P, Serrano-Muñoz D, Comino-Suárez N, Avendaño-López C, Martin-Espinosa N. Electrical microcurrent stimulation therapy for wound healing: A meta-analysis of randomized clinical trials. Journal of Tissue Viability. 2022;31(2):268-277. PMID: 34903470.
- Avendaño-Coy J, Martín-Espinosa NM, Ladriñán-Maestro A, Gómez-Soriano J, Suárez-Miranda MI, López-Muñoz P. Effectiveness of Microcurrent Therapy for Treating Pressure Ulcers in Older People: A Double-Blind, Controlled, Randomized Clinical Trial. International Journal of Environmental Research and Public Health. 2022;19(16):10045. PMID: 36011679.
- Jonik S, Rothka AJ, Cherin N. Investigating the therapeutic efficacy of microcurrent therapy: a narrative review. Therapeutic Advances in Chronic Disease. 2025;16:20406223251361677. PMID: 40821620.
- Martuliak I, Chvála Ľ, Ferenčík M, Fabián V, Slovák M. Efficacy of Rebox Electrotherapy in Pain Management: A Randomized Double-Blind Sham-Controlled Crossover Trial. Pain and Therapy. 2025;14(5):1597-1610. PMID: 40900299.
- Naclerio F, Moreno-Perez D, Seijo M, Karsten B, Larrosa M, García-Merino JÁ, Thirkell J, Larumbe-Zabala E. Effects of adding post-workout microcurrent in males cross country athletes. European Journal of Sport Science. 2021;21(12):1708-1717. PMID: 33295832.
- Gregory WM, Bagley K, Eng S, McMakin C, Del Galdo F. Frequency-specific microcurrent improves hand function and Raynaud's symptoms in scleroderma: results of two pilot studies. Rheumatology (Oxford). 2025;64(10):5504-5508. PMID: 40465410.
- Ofstead CL, Buro BL, Hopkins KM, Eiland JE. The impact of continuous electrical microcurrent on acute and hard-to-heal wounds: a systematic review. Journal of Wound Care. 2020;29(Sup7):S6-S15. PMID: 32654615.
This article is for general informational purposes and does not replace personal medical consultation. Microcurrent therapy (MENS) is a supportive modality; for any new, worsening, or unclear symptoms consult your treating physician or physiotherapist. Contraindications (pacemaker, malignancy, pregnancy, DVT, infection, fever) must be strictly observed. The devices presented are CE-marked medical devices; the cited clinical trials were conducted with different devices and protocols — home device factory programs are tailored for typical user needs. Individual results may vary.
